Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227612 | 0.86 | SMN1; SMN2 (0.32) | ABL1HTR1ASLC6A4 | |
| SCHEMBL7221524 | 0.80 | ABL1 (0.30) | ABL1 | |
| SCHEMBL9020222 | 0.80 | HAO1 (0.38) | ABL1 | |
| SCHEMBL7139756 | 0.80 | ABL1 (0.31) | ABL1 | |
| SCHEMBL2188571 | 0.80 | CA12 (0.43) | — | |
| SCHEMBL7223334 | 0.79 | AOC3 (0.39) | — | |
| SCHEMBL7259643 | 0.78 | KDM4E (0.37) | ABL1PPARGPPARA | |
| SCHEMBL3540870 | 0.77 | LTA4H (0.49) | PPARGPPARA | |
| SCHEMBL7228139 | 0.76 | CTSS (0.39) | ABL1 | |
| SCHEMBL7736894 | 0.76 | CNR1 (0.31) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610722-B2 | Peptidomimetic macrocyclic compounds that comprise a bicyclic imidazolyl moiety and that do not contain thiol moieties; e.g., 3,5-ethano-6,10:12,16-dimetheno-22H-imidazo (3,4-h)(1,8,11,14)oxatriazacycloeicosine-9-carbonitrile | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1332134-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6534506-B2 | For therapy of cancer, neurofibromin benign proliferative disorder; blindness related to retinal vascularization; infections from hepatitis delta and related viruses; prophylaxis of restenosis; polycystic kidney disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-09-05 | — | — | US | disclosed |
| WO-2002060868-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020068747-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-06-06 | — | — | US | disclosed |
| WO-2001077116-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001077114-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068747-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | ABL1 74/4885RHEB 40/4885HTR1A 4872/4885 |
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | ABL1 65/4885RHEB 39/4885HTR1A 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.